a Blood pressure (BP) is known to vary over time within individuals. Although variability between office visits has traditionally been regarded as a barrier to the accurate measurement of BP, several recent studies have reported strong associations between visit-to-visit variability (VVV) of BP and increased risk for cardiovascular outcomes. In this article, we review data on VVV of BP and outcomes, determinants of high VVV of BP including demographics, medical history, and antihypertensive medication classes and poor adherence. In addition, we will discuss methodological issues related to interpreting data from studies of VVV of BP and data on BP variability assessed outside of the office setting. In conclusion, we highlight pressing research needs related to VVV of BP including those aimed at determining the mechanism underlying high VVV of BP, assessing interventions that lower The relationship of mean blood pressure (BP) levels with adverse outcomes [e.g. cardiovascular disease (CVD)] is well established [1-4]. As BP varies over time, and measurements are made at discrete visits, guidelines encourage the use of mean BP as measured at more than one visit to make key treatment decisions (e.g. initiation or dose titration of antihypertensive medications) [5, 6] . In this paradigm, the variability of BP between visits is considered a barrier to accurately assessing an individual's true mean BP level. This paradigm has been challenged by recent data suggesting that visit-to-visit variability (VVV) of systolic BP (SBP) is itself a predictor of coronary heart disease (CHD) and stroke [7] [8] [9] [10] [11] . In some studies, the association between VVV of SBP and outcomes has been stronger than for mean SBP levels [7, 8] . Further, evidence suggests that VVV of BP is reproducible and not a random phenomenon [12, 13] .
The relationship of mean blood pressure (BP) levels with adverse outcomes [e.g. cardiovascular disease (CVD)] is well established [1] [2] [3] [4] . As BP varies over time, and measurements are made at discrete visits, guidelines encourage the use of mean BP as measured at more than one visit to make key treatment decisions (e.g. initiation or dose titration of antihypertensive medications) [5, 6] . In this paradigm, the variability of BP between visits is considered a barrier to accurately assessing an individual's true mean BP level. This paradigm has been challenged by recent data suggesting that visit-to-visit variability (VVV) of systolic BP (SBP) is itself a predictor of coronary heart disease (CHD) and stroke [7] [8] [9] [10] [11] . In some studies, the association between VVV of SBP and outcomes has been stronger than for mean SBP levels [7, 8] . Further, evidence suggests that VVV of BP is reproducible and not a random phenomenon [12, 13] .
In this review, we discuss key issues related to VVV of BP. First, we provide an overview of studies demonstrating a strong, graded association between VVV of BP and the incidence of CVD and all-cause mortality. Second, we discuss correlates of high VVV of BP. In this context, we review data on demographic and clinic factors associated with high VVV of BP, the effect of antihypertensive medication classes and adherence on VVV of BP. We also review possible mechanisms underlying high VVV of BP. Third, we review methodological issues that warrant consideration for planning future studies of VVV of BP. Specifically, we review recently published data on how number of visits, duration of time between visits, number of BP measurements within a visit, and the use of manual versus automatic BP measurement devices affect VVV of BP [14] . In addition, we review data on the different VVV of BP metrics and their correlation with one another. Fourth, we compare and contrast VVV of BP with BP variability assessed on ambulatory BP monitoring (ABPM) and through self-monitoring at home. Finally, we outline future research directions related to VVV of BP.
Visit-to-visit variability of blood pressure and outcomes
Data on VVV of BP and CHD incidence from the Honolulu Heart Program were reported in 1997 [9] . The Honolulu Heart Program included four study examinations conducted at 3-year intervals between 1965 and 1978. Overall, 1408 men completed all four visits and 25 men completed three visits, resulting in an overall sample size of 1433 men. VVV of SBP was calculated and expressed as the variance across these visits. Follow-up for CHD was conducted through 1988. Among those not taking antihypertensive medication, the relative risk for CHD increased progressively across quintiles of variance of SBP and was 5.3 [95% confidence interval (CI): 1.8-15.4] when comparing the highest-to-lowest quintile.
Over the decade following this publication, there were only a few studies of VVV of BP and outcomes [11, 15, 16] . In 2010, Rothwell et al. [7] published data from a series of studies that brought attention back to the association between VVV of SBP and CHD and stroke. Rothwell's publication included the secondary analysis of four large clinical trials. In each of these study populations, VVV of SBP maintained a strong association with the risk for subsequent stroke. For example, comparing the highestto-lowest decile of the SD of SBP, the multivariable adjusted hazard ratio for stroke was 4 Numerous analyses of epidemiological studies and randomized-controlled trials over the past 3 years have confirmed the strong association between VVV of SBP and outcomes reported by Rothwell [8, 10, [17] [18] [19] [20] [21] . Also, the association between VVV of BP and CVD outcomes and all-cause mortality has been extended from select highrisk populations to general population samples [8, 18] . Shimbo et al. [18] reported a strong, graded association between SD of SBP and stroke incidence in a secondary analysis of the Women's Health Initiative. In a fully adjusted model, the hazard ratios (95% CI) of stroke for quartiles 2, 3, and 4 of SD of SBP compared with the lowest quartile (quartile 1) were 1.39 (1.03-1.89), 1.52 (1.13-2.03), and 1.72 (1.28-2.32), respectively. VVV of SBP has been associated with CHD and all-cause mortality in other studies [8, 10, 20] . For example, we found higher levels of VVV of SBP to be associated with increased all-cause mortality ( Fig. 1) [8] . Specifically, among 956 US adults with BP measured three times over 2 months in NHANES III, the multivariable adjusted hazard ratios for all-cause mortality associated with a coefficient of variation of SBP of 3.9-6.7% and Z 6.8%, versus <3.9%, were 1.55 (95% CI: 1.09-2.10) and 1.49 (95% CI: 1.05-2.10), respectively.
Factors associated with high visit-to-visit variability
Higher levels of VVV of BP may result from biological, behavioral, and treatment-related factors. Identifying these factors may help elucidate the mechanisms underlying VVV of BP. However, few data are currently available on correlates of increased VVV of BP. After multivariable adjustment of NHANES III data, older age, female sex, history of myocardial infarction, and higher mean SBP and pulse pressure levels were associated with higher SD of SBP across measurements taken at three visits [8] . Several other factors were associated with higher VVV in partially adjusted models (e.g. African-American race) but were not statistically significant after multivariable adjustment, perhaps because of a limited sample size. In the ASCOT-BPLA, several factors (e.g. older age, female sex, history of stroke) were associated with higher VVV of BP [7] .
Effect of antihypertensive medication classes and visit-to-visit variability of blood pressure
As calcium-channel blockers reduce stroke risk more than can be expected by their effect on mean BP alone, it was hypothesized that they may lower VVV of BP [22] [23] [24] . In a prior analysis of NHANES III, taking any class of antihypertensive medication was associated with higher VVV of BP [8] . In this analysis, VVV of SBP was highest for people taking angiotensin-converting enzyme (ACE) inhibitors, whereas no differences were present for participants taking calcium-channel blockers, thiazidetype diuretics, or b-blockers. However, this study was based on observational data with only 156 participants taking antihypertensive medications. Hazard ratio for all-cause mortality associated with coefficient of variation of systolic blood pressure in the Third National Health and Nutrition Examination Survey Mortality Follow-up Study. Hazard ratios are adjusted for age, sex, race-ethnicity, history of myocardial infarction, mean systolic blood pressure, mean pulse pressure, and use of ACE inhibitors, b-blockers, calcium-channel blockers, and thiazide-type diuretics. Symbol represents point estimate for the hazard ratio; line represents 95% confidence interval. ACE, angiotensin-converting enzyme; SBP, systolic blood pressure.
There are few randomized-controlled trial data directly assessing the effect of antihypertensive mediation classes on VVV of BP. In the ASCOT-BPLA, the SD of SBP across seven follow-up visits was calculated for participants randomized to an atenolol-based regimen (n = 9228) and an amlodipine-based regimen (n = 9302) [25] . The mean SD of SBP was 2.43 mmHg (95% CI: 2.36-2.50 mmHg) higher in the atenolol group (13.42 mmHg) compared with the amlodipine group (10.99 mmHg). In addition, using data from the European Lacidipine Study on Atherosclerosis, Mancia et al. [26] reported a lower VVV of BP for participants randomized to lacidipine compared with atenolol. Specifically, the SD of SBP across an average of eight visits was 8.3 (SD: 3.5) mmHg and 8.8 (SD: 4.0) mmHg in the lacidipine and atenolol groups, respectively (P = 0.007). A meta-analysis of data from over 400 randomized trials comparing antihypertensive regimens (with each other and with placebo) suggested that use of calcium-channel blockers and thiazide-type diuretics leads to lower VVV of BP, whereas use of ACE inhibitors and b-blockers leads to greater variability [25] As individual-level VVV of BP was not available for this meta-analysis, the variance ratio was used as a measure of BP variability. The variance ratio was calculated as the between-individual variance after B1 year of treatment divided by the between-individual variance at baseline. A variance ratio less than 1 indicates lower BP variability. The variance ratio was computed for each arm of each study, and the variance ratios for each class of antihypertensive medications were combined across studies. The variance ratio was 0.81 (95% CI: 0.76-0.86) and 0.87 (95% CI: 0.79-0.96) for calcium-channel blockers and diuretics versus all other drug classes, respectively. In contrast, the variance ratio was 1.16 (95% CI: 1.07-1.25), 1.08 (95% CI: 1.02-1.15), and 1.17 (95% CI: 1.07-1.28) for angiotensin-receptor blockers, ACE inhibitors, and b-blockers, respectively. From this study, the authors concluded that calcium-channel blockers and nonloop diuretic drugs reduced interindividual variation in SBP, whereas angiotensin-receptor blockers, ACE inhibitors, and b-blockers increased it. However, this metaanalysis did not have individual-level data and VVV of BP was not directly calculated. Importantly, prior studies have found that only 50% of the SD of SBP across individuals in a group can be attributed to intra-individual VVV of BP [7] .
Adherence and visit-to-visit variability of blood pressure Low antihypertensive medication adherence is common and has been proposed as a reason underlying high VVV of BP [27] [28] [29] [30] . We studied the association of medication adherence with VVV of BP using data from the Cohort Study of Medication Adherence among Older Adults. The Cohort Study of Medication Adherence among Older Adults enrolled 2094 US adults of at least 65 years of age with diagnosed hypertension taking antihypertensive medication. The analysis of adherence and VVV of BP was limited to 1391 individuals with self-report adherence data, pharmacy fill data for antihypertensive medication, and at least seven clinic visits wherein BP was measured. The eight-item Morisky Medication Adherence Scale, administered three times at annual intervals, captured self-report adherence. On the basis of the average adherence score across the three assessments, scores <6, 6 to <8, and 8 represented low, medium, and high adherence, respectively [31] . Dates of pharmacy fills of antihypertensive medications over the 3-year BP assessment period were abstracted from administrative databases and used to calculate the medication possession ratio (MPR) [32] . The mean (SD) for the within-individual SD of SBP was 12.9 (4.4), 13. However, the correlation between adherence and SD of SBP was low; the Morisky Medication Adherence Scale score and MPR explained 0.6 and 1.9%, respectively, of the variation in the SD of SBP in fully adjusted models (Fig. 2) . These data suggest that low medication adherence may affect, but is not a major determinant of, VVV of BP.
Proposed mechanisms
Impaired endothelial function, inflammation, increased wall stress, baroreceptor dysfunction, and increased sympathetic nervous system activity have each been proposed as possible mechanisms underlying high levels of VVV of SBP. Although few studies have direct measurements of arterial stiffness, pulse pressure is considered a reliable marker [33, 34] . In our prior analysis of NHANES III data, each 10 mmHg increase in pulse pressure was associated with a 0.37 (SE = 0.19) mmHg increase in SD of SBP after multivariable adjustment including mean SBP [8] . Diaz et al. [35] conducted a cross-sectional analysis of endothelial function and SD of SBP among 36 African Americans. Right brachial artery diameter was assessed at rest, during reactive hyperemia (flow-mediated vasodilation), and after nitroglycerin administration (nitroglycerin-mediated vasodilation). SD of SBP was calculated across three visits conducted over a mean of 15 days. In this study, SD of SBP was 6.5±0.8 mmHg among participants with decreased endothelial function versus 5.1±0.6 mmHg among their counterparts with normal endothelial function (P = 0.21). In addition, SD of SBP was higher for those with versus without a flow-mediated vasodilation/nitroglycerin-mediated vasodilation ratio less than 0.48 (6.6±0.7 vs. 4.8±0.7 mmHg, respectively; P = 0.09). In animal models, VVV of BP has been associated with higher levels of C-reactive protein [36, 37] . Interestingly, statins are known to reduce inflammation and individuals randomized to atorvastatin versus placebo in the ASCOT-BPA had lower VVV of SBP during follow-up [25, 38] . Although these data are provocative, more studies investigating the mechanisms underlying high VVV of BP are needed.
Methodological issues
Prior studies of VVV of BP and outcomes have been secondary analyses of randomized-controlled trials or epidemiological studies or retrospective analyses of clinical data. As such, the number of visits used to calculate VVV of BP, number of BP measurements during each visit, and duration of time between visits have varied between and even within studies. In addition, VVV of BP has been reported using a number of different variability metrics (e.g. SD, coefficient of variation, peak, maximum, etc.). There are currently no accepted standards for how to calculate VVV of BP.
Using data from the Trial of Preventing Hypertension (TROPHY) we evaluated the impact of number of visits, number of BP measurements per visit, duration of time between visits and BP measurement device (automatic vs. manual) on levels of VVV of SBP [14] . In this study, the SD of SBP increased with more visits (Fig. 3) . For example, when using the mean of three manual measurements per visit, the SD of SBP was 5.6, 6.8, and 7.7 mmHg across three, seven and 18 visits, respectively. A review of the statistical literature provides theoretical support for an increasing measure of variability with a larger sample size (e.g. number of visits) [39] . Also, in TROPHY, the SD of SBP was higher using an automated versus manual BP measurement device and when using a single BP versus the mean of three BP measurements per visit. Finally, the SD of SBP was larger when calculated using seven visits separated by 8 versus 3 months (7.5 vs. 6.8 mmHg, respectively). The degree to which the association of VVV of BP with CVD outcomes is affected by the measurement properties of VVV of BP is unclear. Nonetheless, these data suggest that several properties affect absolute levels of VVV of BP, VVV of BP should be calculated in a similar way for all participants in a study, and caution is needed before comparing and/or pooling studies of VVV of BP.
Most prior studies of VVV of BP have reported multiple metrics (e.g. SD, coefficient of variation). Whether these metrics provide complementary information is unclear [7, 12] . The most commonly reported VVV metric Intra-individual SD of systolic blood pressure by number of visits among the Trial for Preventing Hypertension placebo group. Intra-individual SD calculated using the mean of three manual blood pressure measurements at each visit; results were similar when visit blood pressure was determined using the first measurement or an automated measurement device [14] . SBP, systolic blood pressure.
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is the SD of SBP. This measure captures the overall variability around an individual's mean BP across several visits. As the SD of BP has maintained a modest correlation with mean BP (rB0.3-0.4), the coefficient of variation and standard deviation independent of the mean (SDIM) have been used in some studies [12, 13] . However, the correlation between SD, coefficient of variation, and SDIM have been reported to be very high (r s > 0.90) suggesting they contain identical information [18] . Other VVV of BP metrics capture different aspects of variability. Average real variability and successive variation are measures of variability from one visit to the next taking into account the ordering of the visits, while range, peak and trough levels, and maximum BP are measures of having an extreme BP value at a visit. In the TROPHY study population, we found that all of the metrics were significantly correlated with each other, and correlations were strongest between SD, SDIM, coefficient of variation, and range and between average real variability and successive variation [40] .
Out of office blood pressure variability compared with visit-to-visit variability of blood pressure BP variability can be determined from ABPM and from home (self-measured) BP monitoring [41] . Calculating VVV of BP is not as practical as conducting ABPM or home BP monitoring. However, several studies have reported a low correlation between VVV of BP and 24-h BP variability [7, 10, 42] . In these studies, the correlation between VVV of SBP and 24-h variability of BP on ABPM ranged from 0.15 to 0.26. This low correlation is not surprising. Physical and emotional stimulation result in BP variability over the course of a day, whereas it is recommended that clinic BP is measured in a controlled setting limiting the influence of external stimuli [6, 43] . Therefore, it appears that variability of BP on ABPM and VVV of BP may represent different phenomena.
The strength of association between VVV of SBP and measures of BP variability on ABPM has been compared in a couple of studies [7, 42] . For example, the hazard ratio of stroke, CHD and pooled stroke, or CHD was determined for VVV of SBP and day-time and night-time SD of SBP from ABPM in the ASCOT-BPLA trial [7] . In this study, the VVV of SBP, represented by the SD (standardized to represent 1 SD increase), during 6-30 months of follow-up was associated with a hazard ratio for stroke, CHD or pooled stroke, or CHD events of 1 an analysis of the European Lacidipine Study on Atherosclerosis, there was no independent association between VVV of SBP or 24-h BP variability with intimamedial thickness or cardiovascular outcomes [42] . Furthermore, day-night change in SBP maintains a strong association with CVD outcomes and there are few data on the prognostic value of VVV of SBP independent of this parameter [44] .
The association of mean BP from home monitoring with cardiovascular outcomes is incontrovertible [45] . Although BP variability from home monitoring has been reported to be associated with total and CVD mortality and CVD incidence, its value above and beyond mean BP has been questioned [46] [47] [48] . Also, the associations of BP variability from home monitoring and VVV of BP with outcomes have not been directly compared. The relative value of VVV of SBP versus 24-h BP variability or BP variability from home monitoring clearly warrants further study.
Future research directions
VVV of BP has emerged as an exciting area of research. However, the value of VVV of BP in routine clinical practice remains unclear. There are several areas of research related to VVV of BP that should be considered high priority. These include evaluating (a) the mechanisms underlying VVV of BP, (b) assessing interventions that lower VVV of SBP, and (c) the utility of VVV of SBP assessed in routine clinical practice for the prevention of CVD events.
There are compelling data on the potential benefit of certain antihypertensive medication classes on VVV of BP. However, patient-level data on the effect of antihypertensive medication classes on VVV of BP are lacking. In addition, recommendations for the control of high BP emphasize lifestyle modification, including weight loss and sodium intake reduction [49] [50] [51] . Although the mean BP lowering effects of lifestyle interventions are well established, little attention has been paid to the efficacy of nonpharmacologic treatment modalities on VVV of BP.
Previous studies have relied on BP measurements obtained by trained research staff following a study protocol at set time intervals. It is unclear how these data translate to real-world settings where BP is often measured using inconsistent or imprecise methods, which can lead to added variability. The reproducibility of VVV of BP is similar in data from randomized-controlled trials and the clinical setting [12, 13] . However, it is not known whether VVV of BP measured in clinical settings has similar associations with outcomes as does VVV of BP measured using research protocols. As electronic medical records are becoming more widely used, the point-of-care calculation of metrics such as VVV of BP is increasingly feasible. Studies of the association between VVV of BP and CVD outcomes using BP measurements collected in routine out-patient care is an important next step in guiding the translation of VVV of BP from controlled settings to real-world clinical practice. VVV of BP is currently not directly used in clinical decision-making. If VVV of BP proves to be a modifiable cause of CVD, it may inform treatment decisions and risk prediction algorithms in the future.
Conclusion
VVV of BP has traditionally been regarded as having little value for assessing a patient's risk for future CVD events. However, several recent studies have reported strong associations between VVV of SBP and CHD, stroke, and all-cause mortality. VVV of BP does not appear to be the result of poor medication-taking behaviors. Biological mechanisms underlying high VVV of BP have been proposed but need to be investigated further. Several areas of research are needed to fill in the substantial gaps in knowledge on VVV of BP. As data continue to accumulate on the association of VVV of BP with outcomes and on interventions to reduce VVV of BP, assessment of VVV of BP may transform how BP measurements are used in patient management. VVV of BP could improve the identification of high-risk patients, risk prediction, and selection of optimum antihypertensive agents.
